Cheng-Jang Wu

Cheng-Jang Wu is a highly experienced scientist specializing in early platform research and process development in the field of immunotherapy. Currently serving as Principal Scientist at Atara Biotherapeutics since February 2021, Cheng-Jang Wu leads CMC technical efforts in developing advanced platforms for virus-specific T cell production and CAR T cell process development for GMP manufacturing. Previously, as Senior Scientist in Preclinical and Translational Sciences, Cheng-Jang Wu optimized EBV CAR T processes and enhanced production yields and product potency. Prior roles include Senior Scientist and Scientist at Fate Therapeutics, contributing to IND-enabling activities for iPSC-derived CAR-T cell products, and a post-doctoral fellowship at the University of California, San Diego. Cheng-Jang Wu holds a Ph.D. in Immunology from Chang Gung University, with earlier experience as a Research Assistant at Chang Gung Memorial Hospital.